Hypothesis

Senescent cells fail to generate the precise, transient autophagy pulse required for OSKM‑mediated reprogramming because constitutive SLC7A5‑mediated leucine uptake keeps mTORC1 active even under starvation conditions. We hypothesize that a combined, short‑lived inhibition of mTORC1 (with rapamycin) and of leucine import (with the SLC7A5 inhibitor BCH) delivered only during days 1‑3 of Yamanaka factor expression will re‑establish the autophagy pulse that drives metabolic reset without triggering oncogenic metabolism or cellular toxicity. In contrast, either rapamycin or BCH alone will not rescue autophagy flux or reprogramming efficiency in senescent cells.

Mechanistic Rationale

• Senescent metabolic lock: Senescent cells exhibit elevated SLC7A5 expression, leading to high intracellular leucine that sustains mTORC1 signaling irrespective of extracellular nutrient levels [5]. This blocks the ULK1‑dependent initiation of autophagy, preventing the timely dismantling of the differentiated proteome needed for pluripotency.
• Autophagy as a biosynthetic fuel: During successful reprogramming, autophagy provides amino acids for de‑novo protein synthesis that builds the pluripotency network [1][2]. The autophagy pulse must be transient; prolonged activation shifts metabolism toward a tumor‑like state [6] and impairs function [4].
• Temporal window: Rapamycin enhances iPSC formation when given at day 1 but inhibits it at day 3, indicating that autophagy must be active early and then subside [3]. A dual‑hit strategy that briefly lowers both mTORC1 activity and its upstream leucine signal should mimic the natural starvation‑induced autophagy pulse without overshooting.

Experimental Design (Testable & Falsifiable)

1. Cell model: Human fibroblasts induced into senescence (irradiation or oncogenic RAS).
2. Treatment groups (n ≥ 3 replicates each):
   • Control (OSKM only)
   • OSKM + rapamycin (day 1‑3)
   • OSKM + BCH (day 1‑3)
   • OSKM + rapamycin + BCH (day 1‑3)
   • OSKM + rapamycin + BCH (day 4‑6) – timing control
   • OSKM + rapamycin + BCH + leucine rescue (excess leucine added) – specificity control
3. Readouts:
   • Autophagy flux: LC3‑II/I ratio and p62 degradation via immunoblot at 12 h intervals (days 0‑4).
   • Reprogramming efficiency: TRA‑1‑60⁺ colony count at day 14.
   • Pluripotency marker expression: OCT4, SOX2, NANOG qPCR.
   • Safety/oncogenic readouts: Ki‑67 proliferation, soft‑agar colony formation, and RNA‑seq for metabolic signatures (glycolysis, TCA, nucleotide synthesis) at day 7.
   • Cell viability/apoptosis: Annexin V/PI flow cytometry.
4. Predictions:
   • Only the day 1‑3 rapamycin + BCH group will show a sharp, transient autophagy peak (LC3‑II increase at day 2, return to baseline by day 3) matching the kinetics seen in young fibroblasts.
   • This group will achieve significantly higher reprogramming efficiency than either single agent or controls (p < 0.01, ANOVA with post‑hoc Tukey).
   • The dual‑inhibition group will not exhibit increased soft‑agar colony formation or glycolytic shift, indicating avoidance of oncogenic metabolism.
   • Adding excess leucine will abolish the autophagy pulse and reduce reprogramming to control levels, confirming leucine dependence.
   • Delayed dual inhibition (day 4‑6) will fail to rescue autophagy or improve efficiency, confirming the critical temporal window.

Falsifiability

If the rapamycin + BCH combination during days 1‑3 does not produce a transient autophagy pulse, does not improve reprogramming efficiency beyond single agents, or induces oncogenic phenotypes, the hypothesis is falsified. Conversely, if a transient pulse and improved safety/efficiency are observed only under these conditions, the hypothesis gains strong support, positioning autophagy modulation as a nutrient‑sensing rheostat rather than a simple damage‑clearance pathway.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC11113636/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC7024839/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC4207015/ [4] https://doi.org/10.1038/s41419-019-1464-x [5] https://doi.org/10.1083/jcb.201610113 [6] https://pmc.ncbi.nlm.nih.gov/articles/PMC8834004/